Sam­sung out­lines block­buster in­vest­ment plan for bio­phar­ma­ceu­ti­cals, part of a $22B play on next-gen tech

Af­ter build­ing up a biosim­i­lars group and branch­ing out in­to new drug de­vel­op­ment, Sam­sung says it plans to make a big push on the bio­phar­ma­ceu­ti­cals front over the next three years, lin­ing up $22 bil­lion to make this one of sev­er­al growth ar­eas for the con­glom­er­ate.

There aren’t a lot of de­tails to go with this. Sam­sung — un­der pres­sure from Chi­nese ri­vals — broad­ly said that it’s ready to wa­ger $22 bil­lion on next-gen tech­nolo­gies, not­ing a big in­ter­est in AI, au­to elec­tron­ics and bio­phar­ma, ac­cord­ing to the Fi­nan­cial Times.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER